In an article for Life Science Leader, partners Sally Wagner Partin, Sharon Flanagan, and Torrey Cope examine how artificial intelligence is reshaping life sciences M&A by changing the pace and economics of drug development. They explore how AI’s growing role in target identification, clinical development, and regulatory decision-making is influencing valuation, due diligence, milestone structures, transaction timing, and risk allocation, and outline key considerations for dealmakers as AI continues to transform the life sciences industry.
